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Human induced pluripotent stem cells (iPSCs) provide great potential as a tool for 
basic biological discovery, disease modeling, and ultimately for cell based regenerative 
medicine but the full realization of these stem cells requires an ability to precisely edit 
their genome in an efficient way. The relative efficiencies of CRISPR/Cas9 and TALENs 
were quantified in human iPSC lines for inducing both homologous donor-based precise 
genome editing and nonhomologous end joining (NHEJ)-mediated gene disruption; 
genome wide off-target mutagenesis was also assessed by targeted deep sequencing. The 
specificity of Cas9 was further tested by targeting either the mutant or the wild-type allele 
of disease causing single nucleotide variants (SNVs) with gRNAs and testing their 
cleavage at the intended target or the other genotype differing by a single nucleotide; 
little disruption was observed at the other allele differing by a single nucleotide alone. 
Overall, these results demonstrate the advantages of the CRISPR/Cas9 system in allele-
specific genome targeting and in NHEJ-mediated gene disruption while they were 
comparable in HDR efficiencies. To further investigate the specificity whole genome 
sequencing was performed on iPSCs successfully edited with either CRISPR/Cas9 or 
TALENs and found no evidence of mutations at other sites similar to the nuclease 
binding sequence.  To utilize these genome editing tools for a relevant biological 
phenotype, genetic variation associated to platelet aggregation was chosen for further 
characterization. The platelet endothelial aggregation receptor 1 (PEAR1) gene was 
knocked out (KO) using CRISPR/Cas9 and compared to the otherwise isogenic iPSCs to 
determine its influence on hematopoiesis and megakaryopoiesis. PEAR1 KO iPSCs were  
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found to increase cell proliferation as well as increase megakaryocyte lineage 
commitment. Additionally an intronic SNP, rs12041331, reported to reside within a 
putative enhancer was deleted along with the surrounding 251 bp which resulted in a 
significant reduction of PEAR1 mRNA levels. This reduction was primarily observed on 
the same allele as the deletion indicating a cis-acting mechanism of gene regulation. 
Overall this thesis demonstrates the efficiency and specificity of genome editing in 
human stem cells and their use towards precise genetic modification for functional 
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During the natural course of human embryogenesis the single cell composing the 
zygote contains all the genetic information and potential to produce an adult human 
capable of perpetuating the cycle once more. After a certain stage of embryogenesis no 
pluripotent stem cells remain with the potential to differentiate into all cells of the body 
leading to a state of minimal self-repair that cannot recover from severe injury or disease. 
While the sequence of DNA in the nucleus has not changed in the adult, its epigenetic 
landscape has been corralled into a Waddington final state incapable of return to the 
summit, or so it seemed until cellular reprogramming was discovered first by John 
Gurdon in frogs. In 1958 Gurdon first successfully cloned a Xenopus by transferring a 
nucleus derived from a tadpole into an enucleated egg (Gurdon et al. 1958). Then some 
set of unknown factors in the nucleus of the egg “reprogrammed” the nucleus of the 
somatic cell back to an embryonic state that was capable of populating the entire frog. 
For decades the work was not reproduced by others and largely ignored until Dolly the 
sheep was cloned by Somatic Cell Nuclear Transfer (SCNT) proving this technique was 
also applicable to mammals. Using a brute force reductionist approach Shinya Yamanaka 
found that four simple transcription factors, OCT4, SOX2, KLF4 and cMYC could 
reprogram an adult cell back to an embryonic like state capable of self renewal and the 
capacity for differentiation into all cell types that he called induced Pluripotent Stem 
Cells (iPSCs) (Takahashi and Yamanaka 2006). These iPSCs are a tremendously 
powerful tool to contribute to basic biological research, disease modeling and have 
potential applications in autologous cell based regenerative medicine.  
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DNA sequencing technology has been steadily improved over the past four 
decades leading to the throughput necessary to sequence a draft version of the human 
genome (Venter 2001; Lander 2001). The cost of sequencing continued to drop with the 
development of new methods for DNA sequencing that include pyrosequencing, 
sequencing by ligation, and reversible terminator chemistry that all implemented 
massively parallel techniques to dramatically increase the throughput and cost efficiency 
of reading DNA. This ushered in a new era of DNA sequencing both for basic biological 
research as well as many new tests for genetic disorders. After more than three billions 
years of evolution into ever more complex chemical, cellular, and technological creatures 
we are apertures for the cosmos to know itself; which for the first time has gazed back 
upon the chemical nature of our transition from the inanimate into the living through 
information contained in DNA. Starstuff powered by starlight seeking to better 
understand where we came from to help facilitate our path into the future. 
Horizontal gene transfer is the most diverse and abundant tool by which evolution 
has used time and time again to manipulate the genomes of all life on Earth. By 
mimicking simple natural systems man was able to use viruses and other gene delivery 
systems to insert foreign DNA into bacteria, plants and animals. Although these methods 
could be quite efficient at gene delivery, controlling the site and number on integrations 
in the host cell was problematic and could lead to transgene silencing or oncogenic 
transformation in the case of in vivo therapies. Genome editing using a homologous DNA 
donor relies on spontaneous generation of DNA double strand breaks (DSB) to 
recombine the exogenous donor template with genomic DNA to induce a desired  
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mutation and has been widely used in mouse and many other model organisms but has 
been difficult to use in human stem cells due to poor survival of single cells, and orders 
of magnitude lower efficiency of recombination. To increase the efficiency of 
recombination DNA binding domains such as Zinc Finger domains were combined with a 
Fok1 nuclease domain to generate Zinc Finger Nucleases (ZFNs) which allowed 
successful gene targeting at several endogenous loci in the human genome (Zou and 
Maeder et al. 2009; Zou and Mali et al. 2011). Although ZFNs greatly facilitated the 
genome editing process they were difficult to design and relied on companies to assembly 
and test many finger combinations before a final tool was developed. Transcription 
activator like effector nucleases (TALENs) were also developed from DNA binding 
domains secreted by Xanthomonas bacteria to influence plant gene expression. TALENs 
could target a broader range of sequences than ZFNs and were dramatically easier to 
synthesize and clone (Li et al. 2011; Cermak et al. 2011). The latest technology for 
genome editing to emerge is the Clustered Regularly Interspaced Short Palindromic 
Repeats (CRISPR)/ Cas9 derived from an adaptive bacterial immune system which uses 
single guide RNAs (gRNAs) to target and cleave specific DNA sequences (Jinek et al. 
2012). This system has been repurposed for eukaryotic expression and has been shown 
effective in a broad range of animal models and human cell lines including iPSCs (Mali 
et al. 2013a; Cong et al. 2013).  
This thesis aims to compare and contrast TALENs and CRISPR/Cas9 as a robust 
new tool for genome editing human stem cells as well as to perform functional 
interrogation of genetic variation associated with a relevant biological and medical  
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phenotype, platelet aggregation. The first aim investigated the specificity of Cas9 by 
predicting the most similar sites in the genome to the gRNA sequence and PCR amplify 
these sites in bulk transfected cells followed by deep sequencing to determine their indel 
mutation rate at sites other than the intended target; the overall efficiencies of NHEJ and 
HDR were also measured. The second aim probed deeper into genomic integrity after 
genome editing using whole genome sequencing (WGS) to evaluate the mutation rate 
genome wide and search for mutations similar to the DNA binding site of TALENs or 
Cas9/gRNA nucleases. Finally the third aim of the thesis involved applying these tools 
for precise genome editing towards a biological phenotype of platelet production and 
aggregation by modifying the platelet endothelial aggregation receptor 1 (PEAR1) gene 
to interrogate its function. The PEAR1 coding sequencing and putative enhancer were 
knocked out and compared to otherwise isogenic parental iPSCs from which they were 
derived to isolate specific genetic effects and determine their role on hematopoietic 
differentiation followed by megakaryocyte maturation. Together with next-generation 
DNA sequencing that uncovers genetic variations, this study demonstrated an approach 
and feasibility to precisely edit DNA at a selected locus and to determine the causal 
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Aim 1: Compare the efficiency and specificity of human 
genome editing stimulated by TALEN, and CRISPR/Cas9 in 
human iPSCs. 
Efficient and precise genome editing is crucial for realizing the full research and 
therapeutic potential of human iPSCs. Engineered nucleases including CRISPR/Cas9 and 
TALENs provide powerful tools for enhancing gene-targeting efficiency. In this study, 
we investigated the relative efficiencies of CRISPR/Cas9 and TALENs in human iPSC 
lines for inducing both homologous donor-based precise genome editing and 
nonhomologous end joining (NHEJ)-mediated gene disruption. Significantly higher 
frequencies of NHEJ-mediated insertions/deletions were detected at several endogenous 
loci using CRISPR/ Cas9 than using TALENs, especially at nonexpressed targets in 
iPSCs. In contrast, comparable efficiencies of inducing homologous donor-based genome 
editing were observed at disease-associated loci in iPSCs. In addition, we investigated the 
specificity of guide RNAs used in the CRISPR/Cas9 system in targeting disease-
associated point mutations in patient-specific iPSCs. Using myeloproliferative neoplasm 
patient-derived iPSCs that carry an acquired JAK2-V617F point mutation and α1-
antitrypsin (AAT) deficiency patient-derived iPSCs that carry an inherited Z-AAT point 
mutation, we demonstrate that Cas9 can specifically target either the mutant or the wild-
type allele with little disruption at the other allele differing by a single nucleotide. 
Overall, our results demonstrate the advantages of the CRISPR/Cas9 system in allele-
specific genome targeting and in NHEJ-mediated gene disruption. 
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AIM 1 INTRODUCTION 
Techniques to edit genomic DNA at a precise locus in human iPSCs present an 
unprecedented potential for regenerative medicine as well as disease modeling of genetic 
variants. The efficiency of multiple published techniques in human iPSCs has been 
extremely low until the development of engineered nucleases such as zinc finger 
nucleases (ZFNs), transcription activator like effector nucleases (TALENs), and 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas systems (Zou 
et al. 2009; Hockemeyer et al. 2009; Hockemeyer et al. 2011; Mali et al. 2013a; Cong et 
al. 2013; Damian et al. 2013). ZFNs and TALENs are fusion proteins, in which Fok1 
nuclease domain is fused to a DNA binding domain that can bind to and cleave a specific 
DNA sequence of interest. Once a targeted double strand break (DSB) has been 
introduced, the DNA is repaired by the cell’s endogenous DNA repair machinery through 
one of two pathways. The error-prone NHEJ pathway often results in small insertions or 
deletions (indels), while the Homology-directed Repair (HDR) pathway results in precise 
repair with a homologous chromosome or an exogenous donor template. These 
engineered proteins acting as designer nucleases proved to be an efficient means to target 
and manipulate the genome for both gene knock out (KO) and knock in (KI) experiments. 
Compared to ZFNs, design of a pair of TALENs is more feasible for most laboratories 
and favored by many investigators. However, a pair of TALENs, each has ~15 peptide 
modules of 33-amino-acid units, still takes time to synthesize and test to ensure its 
efficiency as well as specificity. 
In comparison to a pair of TALENs, the CRISPR-Cas type II is more user friendly  
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as the protein component (Cas9) remains the same while the short RNA components for 
one or multiple targets can be rapidly designed and synthesized. The system was 
originally identified to have three essential components: (i) Cas9 endonuclease, (ii) 
CRISPR RNA (crRNA) to bind the complementary DNA target, and (iii) trans-activating 
RNA (traRNA) to associate crRNA to Cas9. This was further reduced to two components 
by fusing the traRNA and crRNA to a single guide RNA (gRNA) (Jinek et al. 2012). 
Cas9 has been adapted for better expression in mammalian cells and was shown to be an 
efficient and adaptable tool in human cell lines including iPSCs (Mali et al. 2013a; Cong 
et al. 2013). 
In order to gain a better understanding of the advantages and disadvantages of 
CRISPR/Cas9 and TALENs technologies in human iPSCs, we compared the efficiency of 
Cas9-gRNAs versus TALENs in targeting disease-associated loci. We investigated their 
efficiencies by measuring both NHEJ-mediated indel mutations and homologous donor-
based precise gene editing. The model disease genes we used include JAK2, in which an 
acquired somatic point mutation (JAK2-V617F) occurs in approximately 95% of patients 
with polycythemia vera (PV) (Levine et al. 2008), and the SERPINA1 gene, in which an 
inherited point mutation (AAT Z-mutation) causes α1–antitrypsin (AAT) deficiency 
(Carrell et al. 2002). We also included the previously validated Cas9-gRNA and TALEN 
designer nucleases targeting the AAVS1 locus commonly used as a “safe harbor” in the 
human genome for stable transgene expression (Hockemeyer et al. 2009; Smith et al. 
2008; Lombardo et al. 2011; Zou et al. 2011; Zou et al. 2012).  
Concerns were raised over the specificity of the CRISPR/Cas9 system, when  
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reports using human cell lines detected NHEJ- mediated off-target mutations at loci with 
up to five mismatches to the gRNA (Hsu et al. 2013; Fu et al. 2013). As this was further 
investigated in other biologically relevant samples such as mouse and nonhuman primate 
embryos and human adult stem cells, off-target effects were not detected or minimal (Niu 
et al. 2014; Wu et al. 2013; Wu et al. 2014; Yang et al. 2013a; Yang et al. 2013b; Yin et 
al. 2014; Smith et al. 2014). In this aim we investigated the specificity of Cas9-gRNAs in 
human iPSCs in stimulating both NHEJ-mediated indel induction and donor-based 
genome editing by targeted deep sequencing of whole iPSC populations treated with 
Cas9-gRNAs. 
The high specificity of Cas9-gRNAs also prompted us to investigate whether this 
technology can facilitate allele-specific targeting at point mutations in patient-specific 
and normal iPSCs. For this purpose, we used a variety of integration-free human iPSC 
lines including PV-iPSC lines that carry the JAK2-V617F mutation, AAT deficiency-
iPSC lines that carry the Z-AAT mutation, and control BC1 iPSC line whose genomic 
integrity has been characterized in detail by next generation sequencing (Cheng et al. 
2012) (Table 1). We designed gRNAs targeting either the mutant or the wild-type allele 
and examined their efficiency in disrupting or correcting the intended target allele or the 






AIM 1 METHODS 
Maintenance and expansion of human iPSCs 
Human iPSCs were cultured with E8 medium (Life Technologies, Carlsbad, CA) 
on tissue culture plates coated with Matrigel (BD Biosciences, San Jose, CA) or 
Vitronectin (Life Technologies) as previously described (Chen et al. 2011; Wang et al. 
2013). For routine passaging, iPSCs were digested with Accutase (Sigma, St. Louis, MO) 
for 5 minutes and washed with PBS by centrifugation at 200g for 5 minutes. Digested 




 with E8 medium supplemented with 
10 µM ROCK Inhibitor Y-27632 (Stemgent, Cambridge, MA) for the first 24 hours. 
 
Expression vectors used in CRISPR/Cas9 and TALEN experiments 
We used the CRIPSR/Cas9 system previously described (Mali et al. 2013a), for 
which an expression vector encoding humanized (h) Cas9 protein was obtained from 
Addgene.org (Plasmid #41815). 455-bp guide RNA (gRNA) expression cassettes 
including 20-bp target-specific sequence for each locus were synthesized (Integrated 
DNA Technology, Coralville, IA). The JAK2 and SERPINA1 gRNAs were synthesized 
as Gene Blocks and cloned into Zero-blunt TOPO vector (Life Technologies). The 
AAVS1 gRNA-T2 was obtained from Addgene.org (Plasmid #41818). TALEN 
constructs targeting the AAVS1 and AAT loci have been described in previous 
publication (Yan et al. 2013; Porteus et al. 2006). The JAK2 TALENs were constructed 
with the Joung Lab’s REAL Assembly TALEN Kit (Addgene #1000000017) following 
published protocol (Reyon et al. 2012). The Cas9-gRNA and TALENs targeting each  
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locus were first validated using a GFP reporter system in 293T cells. 
 
MiSeq-based deep DNA sequencing of endogenous loci after transient expression of 
engineered endonucleases  
Human iPSCs were digested with Accutase for 5 minutes and the single cells 
were washed once with PBS. 2×10
6
 iPSCs were then resuspended in 100 µl of P3 
Primary Cell Solution (Lonza, Frederick, MD) supplemented with 2.5 µg of hCas9 
plasmid and 2.5 µg of gRNA plasmid, and then nucleofected in 4D-Nucleofector (Lonza) 
using the hES H9 program. In TALEN experiments, 2.5 µg of each TALEN expression 
vector were used. The nucleofected iPSCs were then plated onto Matrigel-coated plates 
in E8 medium supplemented with 10 µM Y-27632. Three days after the transfection, all 
the cells were harvested and the genomic DNAs were isolated using DNeasy Blood and 
Tissue Kit (Qiagen, Hilden, Germany). The genomic regions of interest were PCR 
amplified using Phusion DNA polymerase (New England Biolabs, Ipswich, MA). PCR 
products purified by PCR Purification Kit (Qiagen) were deep sequenced by MiSeq 
Personal Sequencer (Illumina, San Diego, CA) and demultiplexed using ea-utils program 
Fastq-Multx only allowing reads in which both paired ends agreed yielding an average 
coverage of >300,000 reads per sample. Reads for each sample were aligned using 
bowtie2 and the indel percentage was calculated by the number of reads with indels 
around 20-bp of the putative cutting site divided by the total number of aligned reads. 
Sequencing data was deposited at the Short Read Archive (SRA) with the accession 
number SRP042279. 
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Amplification and sequencing of putative off-target binding sites of gRNAs 
To bioinformatically predict the off-target binding sites of three gRNAs (gR-
AAVS1-T2, gR-JAK2-F and gR-PEAR1) a list of all sites in hg19 within five 
mismatches to the gRNA that were followed by a PAM sequence (NRG) was generated 
using the EMBOSS tool fuzznuc. The lists were ranked based on likelihood of cleavage 
predicted by an experimentally determined weighting algorithm (Hsu et al. 2013). Using 
Primer3, oligos were designed to amplify the top 15 putative off-target loci for each 
gRNAs which were independently transfected with Cas9 into iPSCs and 293T cells. After 
96 hours, cells were harvested and gDNA was extracted with DNeasy Blood & Tissue 
Kit (Qiagen) and the intended targets (4) and predicted off-targets (60) were PCR 
amplified using Phusion DNA polymerase. Amplicons were pooled into four conditions: 
(i) parental iPSCs; (ii) iPSC Cas9/gRNA targeted; (iii) HEK293T parental; and (iv) 
HEK293T Cas9/gRNA targeted which underwent Kapa Biosystems–High-Throughput 
Library Prep Kit (Product # KK8234) for the MiSeq 500 cycle sequencing chemistry. 
Reads were aligned using bowtie2 and indel mutation rates for each of the amplicons was 
calculated as previously described (Hsu 2013). 
Homologous donor-based gene targeting in human iPSCs 
In homologous donor-based experiments targeting JAK2 or SERPINA1 loci, 
2×10
6
 patient-specific iPSCs cells were resuspended in 100 µl P3 Primary Cell Solution 
supplemented with either (i) 2.5 µg hCas9 plasmid, 2.5 µg of guide RNA plasmid and 5 
µg HR donor vector; or (ii) 2.5 µg plasmid coding TALEN-left, 2.5 µg of TALEN-right 
and 5 µg HR donor vector. In experiments targeting AAVS1 locus, 2 million BC1 iPSCs  
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were nucleofected with either (i) 5 µg AAV-CAGGS-EGFP (addgene # 22212), 3 µg 
each of a heterodimeric TALEN pair targeting the AAVS1 (Porteus 2006) or (ii) 5 µg 
AAV-CAGGS-EGFP (Addgene # 22212), 3 µg hCas9 (Addgene #41815), and 3 µg 
AAVS1-T2 gRNA (Addgene #41815). The nucleofected iPSCs were plated onto 
Matrigel-coated six-well plates (nine wells per sample in AAT targeting experiments; 12 
wells per sample in JAK2 and AAVS1 targeting experiments) immediately following 
nucleofection. 10 µmol/l ROCK Inhibitor Y-027632 was added in the E8 medium for the 
first 24 hour. There is no cell passaging between the initial plating and colony picking. 
Medium was replaced on a daily basis. Starting at 96 hours after nucleofection, 
puromycin (0.5 µg/ml) was added to the medium for the selection of targeted events. 
After puromycin selection, colonies were manually picked from different wells (e.g., two 
colonies were picked from each individual well in the AAT experiments) and expanded. 
We also tried to avoid picking colonies that grew close to each other. Genomic DNAs 
were isolated from the expanded clones and analyzed for targeted integration. 
  
Statistical analyses 
MiSeq sequencing data analysis was performed as previously described (Hsu et 
al. 2013). Statistical significance for targeted DNA amplicon sequencing was determined 
using the upper tail test of population proportion comparing each targeted sample to the 
untransfected control (α = 0.05). To adjust for multiple comparisons the bonferroni 






AIM 1 RESULTS 
Cas9-gRNAs are superior to TALENs in inducing NHEJ-mediated indel mutations 
 We evaluated the efficiency of Cas9-gRNA versus TALEN in targeting multiple 
endogenous loci in human iPSCs. We first determined, by MiSeq deep sequencing, the 
frequencies of small indels resulting from NHEJ-mediated DNA repair of DSBs caused 
by either Cas9 or TALENs in the absence of an exogenous donor template (Figure 1). 
Cas9 and the guide RNA (gR-JAK2-F) designed to target the JAK2-V617F mutation 
were compared to a pair of JAK2-TALENs designed to target the same JAK2-V617F 
region. Cas9 and the guide RNA (gR-AAT-Z) designed to target the Z-AAT mutation 
were compared to a pair of AAT-TALENs that previously have been shown to efficiently 





In addition to these designer nucleases targeting disease-associated mutations, previously 
reported Cas9-gRNA (gR-AAVS1-T2) and TALENs targeting the AAVS1 safe harbor 
locus were also used in this study (Mali et al. 2013a; Porteus et al. 2006). These Cas9-
gRNA or TALEN expression vectors were first tested in 293T cells using a previously 
reported GFP reporter system to validate their functionality. They were then transfected 
into three human iPSC lines with appropriate target sequences (Table 1-1). Three days 
after transfection, the genomic DNA was amplified by high- fidelity PCR using primers 
flanking the common targeted DNA region shared by both designer nucleases for each 
locus. MiSeq analysis of these PCR-amplified regions revealed significantly higher indel 
rates at all three endogenous loci after Cas9 targeting than TALENs (Figure 1-2). At all 
three loci, Cas9-gRNAs induced between 10- and 100-fold more indels than did TALENs 
in human iPSCs, reaching the level of 0.7–2.5% mutation rates. 
 
Comparable efficiencies between Cas9-gRNAs and TALENs in facilitating genome 
editing by homologous donors 
One common approach in precise genome editing is to introduce a homology donor 
together with the engineered endonucleases into the target cells. To assess the ability of 
Cas9-gRNAs and TALENs in promoting homology-directed repair, we conducted gene 
targeting experiments with homologous donors at JAK2, SERPINA1, and AAVS1 loci in 
the same human iPSCs as we did in the MiSeq/NHEJ experiments. We designed an HR 
donor template with homology arms near the Cas9-gRNA and TALEN cutting sites at the 
JAK2 locus (Figure 1a). Previously reported HR donors shown to successfully target the 
AAT Z-mutation by ZFN and TALEN technologies (Yan et al. 2013; Ye et al. 2009) and  
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the AAVS1 locus (Hockemeyer et al. 2009) were also used (Figure 1b,c). In each 
targeting experiment, 2×10
6
 iPSCs were cotransfected with a homology donor vector and 
either the Cas9-gRNA or the TALENs. iPSC colony numbers were counted after 
puromycin selection, and iPSC clones were randomly picked and expanded. Genomic 
DNA isolated from each clone was used for PCR screening for targeted integration (TI) 
events. The absolute targeting efficiencies were calculated as “targeted integration events 
per million input cells” based on (i) the percentage of randomly selected iPSC clones that 
are positive for TI; (ii) the total colonies after puromycin-selection; and (iii) the total 
input cells (Table 1-2). In contrast to what was observed in the NHEJ experiments, 
transfection of Cas9-gRNA and TALENs designed to target each locus resulted in 
comparable efficiencies; the largest difference was observed at the AAVS1 site targeting 












Figure 1-1 Genomic loci targeted by Cas9-gRNAs and transcription activator like 
effector nucleases (TALENs) in human induced pluripotent stem cells (iPSCs). (a) 
The genomic structure and nucleotide sequence around JAK2-V617F mutation in JAK2 
gene are shown. Exon sequence is shown in uppercase. The G to T point mutation in 
exon 14 is indicated. A diagram of the donor vector used in HR-based JAK2 targeting 
(Tables 2 and 3) is shown. The vertical arrow indicates the G>T point mutation in JAK2-
V617F. The PGK-puroΔtk dual selection cassette was flanked by piggyBac (PB) 5′ and 3′ 
inverted terminal repeats to facilitate potential footprint-free genome editing after PB-
transposase-mediated excision. The vectors contain JAK2 homology arms flanking the 
putative Cas9-gRNA and TALEN cutting sites. (b) The genomic structure and nucleotide 
sequence around Z-AAT mutation in SERPINA1 gene. The G to A variant in exon 5 is 
indicated. The diagram of a previously reported donor vector used in AAT targeting is 
shown. (c) The genomic structure and nucleotide sequence in intron 1 of the PPP1R12C 
gene. The diagram of a previously reported donor vector used in AAT targeting is shown. 
Recognition sequences of Cas9-gRNA (boxed, PAM sequences shown in green) and 
TALENs (underlined) are shown at each locus. PCR primers for identifying targeted 
integration events (red arrows) and or un-targeted allele (black arrows) are shown. HA-L, 








Figure 1-1 Genomic loci targeted by Cas9-gRNAs and transcription activator like 









High specificity of CRISPR/Cas9 in human iPSCs revealed by genome-wide 
targeted deep sequencing 
We next determined the specificity of the gRNAs that together with Cas9 generate 
indels in human iPSCs at much higher efficiency than TALENs. We also used MiSeq 
deep sequencing to determine indel frequencies at potential off-target loci with DNA 
sequences similar to the intended locus. The potential off-target loci were predicted using 
a previously described bioinformatics program (Hsu et al. 2013), and the top 14–15 loci 
were measured together with the intended loci (JAK2 and AAVS1) in the same 
experiments (Figure 1-3). In addition to human iPSCs, we also measured indel 
frequencies induced by these same Cas9-gRNAs in the widely used human 293T cell line 
using the same Miseq strategy (Figure 1-3). After transfection with Cas9 and gRNAs, 
genomic DNA was isolated from the entire transfected population. Upon successful PCR 
amplification, these loci were analyzed by MiSeq in comparison to those in their parental 
(un-transfected) cells. Among the 29 most likely off-targets of the two gRNAs, 
statistically significant indels were detected in 22 of them in 293T cells (Figure 1-3). Two 
of the most significant AAVS1 off- targets each had >10% of absolute indel rates and 
were >100-fold higher than observed in the controls (OT-5: 9683/63422 (15.27%) versus 
130/401234 (0.03%), P < 2.2 × 10-16; OT-8: 14261/121156 (11.77%) versus 40/59427 
(0.07%), P < 2.2 × 10-16). In comparison, overall NHEJ rates in iPSCs were ~50-fold 
lower than those in transfected 293T cells (Figure 1-3). AAVS1 OT-5, with less than 5% 
of the on-target efficiency, is the only site that showed statistically significant indels in  
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the targeted iPSCs (Figure 1-4). These results demonstrated the high specificity of Cas9-
gRNAs in human iPSCs as compared to 293T cells that have an overall higher level of 

















Figure 1-3 Targeted genome-wide deep sequencing of potential off-targets reveals 
high specificity of CRISPR/Cas9 in human induced pluripotent stem cells (iPSCs). 
Summarized results of targeted deep sequencing of the 29 bioinformatically predicted 
most likely off-targets in the human genome. For each Cas9-gRNA, the indel frequencies 
(x axis) of their intended target and each potential off-target (OT) in the transfected cells 
(shown in blue) are shown in comparison to the background (DNA from parental cells, 
shown in red). The mismatched nucleotides of each off-target are shown. The PAM 
sequence of the target and putative off-targets are shown in green. PVB1.4 (homozygous 
JAK2-V617F mutation) and BC1 (normal control) iPSC lines were used for JAK2 and 
AAVS1 targeting, respectively. Note that the guide RNA gR-JAK2-F used in this study 
was designed to target the JAK2-V617F mutation; therefore a single nucleotide mismatch 
is present in the 293T JAK2 locus. *Sites with statistically significant (P < 0.05) indels 
above background level. Data represent single transfection and MiSeq experiments.  
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Allele-specific gene targeting at point mutation loci in human iPSCs using Cas9-
gRNAs 
Having demonstrated high specificity of Cas9-gRNAs in genome- wide studies, 
we then investigated the efficiency of targeting specific base pairs in human iPSCs. For 
this purpose, we again chose to target the somatic JAK2-V617F (rs77375493, G>T) 
mutation and the inherited α1-antitrypsin (AAT) Z mutation (rs28929474, G>A) in the 
SERPINA1 gene. Two panels of healthy donor and patient-derived iPSCs carrying either 
a homozygous wild-type target allele, heterozygous mutant allele, or homozygous mutant 
allele were used in these experiments (Cheng et al. 2012; Yan et al. 2013; Choi et al. 
2011; Ye et al. 2014; Ding et al. 2013) (Table 1-1). Two gRNAs, gRNA-JAK2-F, and 
gRNA-JAK2-V, were designed with a single nucleotide difference to specifically 
recognize the V617F mutant allele (T) or the wild-type allele (G) of JAK2 (Figure 1-4a). 
Another pair of gRNAs, gRNA-AAT-Z and gRNA-AAT-M, were designed to 
specifically recognize the AAT Z-allele (A) or the wild-type M-allele (G) (Figure 4b). 
We examined the efficiency and specificity of the two pairs of gRNAs in targeting the 
point mutations at endogenous loci by cotransfection with Cas9 (Figure 1-3). Indel 
frequency analyses of the JAK2 gene revealed that only the gRNA-JAK2-F successfully 
targeted the JAK2 locus in the JAK2-V617F homozygous PVB2.7 and PVB1.4 iPSCs. 
Likewise, only gRNA-JAK2-V successfully targeted the wild-type BC1 and PVB1.11 
iPSCs (Figure 1-4c). The single-nucleotide mismatch between gRNAs and target 
genomic sequence prevented any major indel mutagenesis by Cas9. Similar results were 
observed in AAT targeting. The gRNA-AAT-Z, designed to target the Z-allele, had no  
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detectable effect on the wild-type AAT allele, while significant indels were observed 
after transfection into iPSCs that carry the homozygous Z-mutation. Although a 
statistically significant (compared to the un-transfected control) indel rate was observed 
at the Z-alleles in iAAT3 (homozygous mutant) after gRNA-AAT- M targeting, this indel 
rate (0.055%) is 40-fold lower than that observed after gRNA-AAT-Z transfection 
(Figure 4d). 
For gene/cell therapy and disease modeling, it is often highly desirable to achieve 
precise genome editing based on homologous donors. We therefore evaluated the 
specificity of Cas9- gRNAs in this setting at the endogenous JAK2 and SERPINA1 loci, 
using either the PV-iPSC line iPV183 heterozygous for the JAK2-V617F point mutation 
(Ye et al. 2014) or the iPSC line iAAT5 heterozygous for the Z-AAT point mutation 
(Choi et al. 2013; Choi et al. 2011). To investigate the allelic specificity of inducing 
integration events by Cas9-gRNAs, we cotransfected iPV183 with a homology donor 
template and either Cas9/gRNA-JAK2-F or Cas9/gRNA-JAK2-V, and iAAT5 with donor 
template and either Cas9/gRNA-AAT-Z or Cas9/ gRNA-AAT-M. Candidate targeted 
iPSC clones were randomly picked after cotransfection and puromycin selection 
expanded and screened by PCR and sequencing to confirm targeted integration at the 
targeted allele as well as the sequence integrity of the nontargeted allele. Among the 
expanded PV-iPSC clones, 24/25 and 25/29 had targeted integration by Cas9/gRNA-
JAK2-F and Cas9/gRNA-JAK2-V, respectively. Among the expanded AAT-iPSC clones, 
15/15 and 14/15 had targeted integration by Cas9/gRNA-AAT-Z and Cas9/ gRNA-AAT-
M, respectively. Strikingly, in all 49 clones with targeted integration at JAK2 locus, the  
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integration events occurred only at the JAK2 allele specified by the gRNAs (Table 1-3). 
Similarly there was only one clone from the Cas9/gRNA-AAT-Z experiment that had 
targeted integration in both alleles; in all other clones the integration events occurred only 
at the SERPINA1 allele specified by the gRNAs (Table 1-3). In addition, sequencing of 
each targeted clone showed the absence of NHEJ-mediated mutations on the other non-
targeted allele, further demonstrating the targeting specificity (Table 1-3). Taken 
together, our results from these patient-specific iPSCs strongly suggest the feasibility of 















Figure 1-4 Allele-specific gene targeting of JAK2-V617F and Z-AAT mutations in 
patient-specific induced pluripotent stem cells (iPSCs). (a) Guide RNAs gR-JAK2-F 
and gR-JAK2-V were designed to specifically target the mutant allele (with nucleotide T) 
and wild-type allele (with nucleotide G), respectively. (b) Guide RNAs gR-AAT-Z and 
gR-AAT-M were designed to specifically target the mutant allele (with nucleotide A) and 
wild-type allele (with nucleotide G), respectively. (c) The specificity of gRNA-JAK2-F 
and gRNA-JAK2-V that differ by a single nucleotide were evaluated in iPSC lines with 
V/V or F/F genotype. Human iPSCs with WT JAK2 (BC1 and PVB1.11) or mutant JAK2 
(PVB1.4 and PVB2.7, both are homozygous for JAK2-V617F mutation) were 
cotransfected with Cas9 and either one of the gRNA constructs. The indel frequency at 
the JAK2 locus in each sample is shown. Guide RNA used in each transfection is 
indicated underneath the indel frequency. (d) The specificity of gRNA-AAT-Z and 
gRNA-AAT-M that differ by a single nucleotide were evaluated in iPSC lines with M/M 
(control BC1) or Z/Z (AAT deficiency patient-specific iAAT3, homozygous AAT Z-
mutation) genotype. Major indel events (>0.1%) were only observed when an iPSC line 
was transfected with the gRNA designed for its genotype. Error bars in c and d indicate 
95% Wilson score intervals. N.S., not significant (P > 0.05); *P < 0.001; **P < 2×10–5; 






Figure 1-4 Allele-specific gene targeting of JAK2-V617F and Z-AAT mutations in 
patient-specific induced pluripotent stem cells (iPSCs). 
 
 
AIM 1 DISCUSSION 
This quantitative comparison of Cas9-gRNAs and TALENs at three endogenous 
loci in human iPSCs suggests a higher efficiency of gene disruption by the Cas9 
endonuclease, corroborating with recent studies (Mali et al. 2013a; Yang et al. 2013b; 
Ding et al. 2013). Although not statistically significant, the current study also suggests an 
inverse correlation between gene expression level and the advantage of Cas9 over 
TALEN; the lowest differential indel frequency was observed at AAVS1, which has the 
highest level of expression in human iPSCs among the three genes. Conversely, the most 
advantageous indel induction by Cas9 was observed at the SERPINA1 locus, which has  
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the lowest expression level (based on RNA-Seq data from ENCODE/Caltech,  
GSE33480) (Ding et al. 2013). These data demonstrate that the CRISPR/Cas9 system can 
efficiently target both expressed and nonexpressed loci in human iPSCs, and may have a 
particular advantage at nonexpressed loci. 
In our previous studies, we have observed high efficiency gene targeting at both 
AAT and AAVS1 loci in human iPSCs using TALENs (Choi et al. 2013; Yan et al. 
2013). Therefore, the significantly lower targeting efficiency assayed by indel frequency 
observed in this study was unexpected. We further examined whether the higher rates of 
NHEJ-mediated gene disruption correlate with more efficient gene-editing using donor 
templates with homology arms. We chose to conduct such experiments using the 
conventional drug selection-based donors as we did in previous studies (Choi et al. 2013; 
Yan et al. 2013). Although detecting NHEJ and HDR in the same sets of experiments 
would have been more quantitative, practically this can only be done with a short donor 
template (such as oligonucleotide donors) in order for both events to be detected by 
MiSeq sequencing. The current efficiency of targeting by an oligonucleotide donor, 
however, is still extremely low in human iPSCs on average (Yang et al. 2013b; Soldner et 
al. 2011). Without drug selection, it is technically difficult to identify targeted clones 
before breakthroughs in technology are made. Therefore, we focus on the efficiency of 
the conventional selection-based donor in the current study because it remains a major 
genome-editing tool for most investigators engaged in research using human iPSCs. 
Our quantitative investigation of Cas9 and TALENs in facilitating targeted 
integration events revealed comparable efficiencies of the two technologies (Table 1-2),  
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even though their ability to induce small indels at the same endogenous loci varied 
dramatically (Figure 1-2). There are multiple potential explanations for this. First, the 
difference in binding/releasing kinetics of TALE or Cas9 to genomic DNA (or other 
molecules interacting with either Cas9 or TALENs), may differentially affect the 
subsequent recruitment of the components required for either NHEJ or HDR. As a result, 
TALENs have a relative preference for HDR over NHEJ at induced DSBs. Alternatively, 
TALENs generate a higher percentage of single-strand DNA breaks between their 
binding sites while Cas9- gRNA binding results in more DSBs. Studies using engineered 
DNA nickases have shown that the single-strand DNA breaks can stimulate efficient 
HDR without inducing the error-prone NHEJ pathway (Ramirez et al. 2012; Ran et al. 
2013; Shen et al. 2014). Finally, TALENs typically generate DSBs with single-strand 
overhangs in the space between the two TALE-binding sites while Cas9 has been 
reported to make blunt-end DSBs (Jinek et al. 2012; Maresca et al. 2013). Different types 
of DSBs generated by TALENs and Cas9 may result in different preference for repair 
pathway. We anticipate that future studies at the molecular level of nuclease-DNA 
interaction and in DNA repair pathways may shed light on the exact mechanism, which 
can aid to further improve this gene targeting technology. 
We further examined the specificity of CRISPR/Cas9 system in human iPSCs 
using targeted deep sequencing, which provides the most accurate measurement of small 
indels at endogenous loci (Mali et al. 2013b; Cong et al. 2013; Hendel et al. 2014). While 
a WGS approach offers broad genome coverage with an emphasis on the quality of 
individual clones, the approach used in this study allowed for a more quantitative analysis  
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by examining predicted off-targets in significantly greater depth in the entire cell  
population that has undergone genome editing. Each approach has its own advantages 
and disadvantages. Importantly, we have now demonstrated the high specificity of 
CRISPR/Cas9 in human iPSCs using these complementary methodologies. 
The observed high specificity and efficiency provide a basis for us to conduct 
allele-specific gene targeting of point mutations in patient-specific iPSCs. Targeting two 
disease-associated point mutations, the inherited AAT Z-mutation and the acquired 
JAK2-V617F mutation, in five human iPSC lines, we have shown that each Cas9- gRNA 
almost exclusively targets its intended sequence and generates only background levels of 
indels at the other allele that differs by a single nucleotide alone. Using iPSC lines that 
are heterozygous for either mutation, we have also shown allele-specific targeting in a 
setting that is more critical for making precise editing for molecular therapy purposes. An 
additional advantage of using heterozygous cell lines in this study is that it provides an 
internal control for each Cas9-gRNA and eliminates the experimental variations such as 
transfection efficiency that may compromise the results. 
We anticipate that allele-specific gene targeting can be widely applied to many 
other loci in human iPSCs using the CRISPR/Cas9 technology. It should be noted that 
one limitation of the current technique is that it will require a PAM sequence close 
enough to the variant of interest. In this study, each point mutation is located at the 5th 
nucleotide 5′ of their respective PAM sequence. For other genetic variants that locate 
further from PAM sequences, the specificity of Cas9-gRNAs may decrease. However, for 
certain mutations such as the JAK2-V617F and Z-AAT reported here, it offers a unique  
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targeting specificity that was not easily achieved by previous technologies. Additionally, 
as new PAM sequences become targetable by adapting Cas9 from other species and/or 
through protein engineering, we anticipate that this technique will be applicable to more 






































Aim 2: Investigate the genomic integrity of human iPSCs after 
genome editing by CRISPR/Cas9 or TALENs. 
The ability to precisely modify DNA in human iPSCs has been greatly improved 
by targeted nuclease technologies including CRISPR/Cas9, and TALENs but their 
specificity towards the rest of the genome remains unclear. After initial studies reported 
higher than expected off-target mutagenesis using cancer cell lines, a deeper investigation 
into their specificity was warranted in human iPSCs before further applications in disease 
modeling or regenerative medicine could be applied. Several targeted sequencing, or 
Cas9 capture approaches have been conducted to search for off-target mutagenesis but an 
un-biased genome wide screen was needed to know the full extent of genomic mutations 
acquired during the genome editing process. To this end whole genome sequencing was 
conducted on four iPSC clones derived from a single healthy donor targeted with an 
AAVS1 knock-in stimulated by either TALENs, or CRISPR/Cas9 and compared to DNA 
from parental iPSCs harvested directly before transfection. ~200 SNVs and ~10 indels 
were identified in each clone but none of the mutations were recurrent or similar to the 
nuclease binding site; implying that the mutations were either random or pre-existing in 
the original population and not a result of the genome editing process. These results from 
whole-genome sequencing (WGS) analysis of CRISPR/Cas9 and TALEN-targeted 
human iPSC clones demonstrate that these engineered endonucleases provide efficient 




AIM 2 INTRODUCTION 
Human iPSCs provide renewable cell sources for human biology and disease 
research and the potential for developing gene and cell therapy. Known concerns of 
chromosomal instability and mutagenesis after prolonged culture of human stem cells 
lead to in depth investigation of the genomic integrity after cellular reprogramming to 
generate iPSCs. Initial sequencing of reprogrammed cell lines reported ~6 exonic 
mutations but alarmingly there was a disproportionate number of cancer associated genes 
(Gore et al. 2011). Additional studies confirmed the previously mentioned mutation rate 
but did not find any rise in mutation among genes associated with cancer (Cheng et al. 
2012). However the full utilization of iPSCs requires the ability to precisely edit their 
genome in a targeted manor without the induction of undesired off-target mutations.  
Realization of this potential will rely in part on our ability to precisely edit or 
engineer the human genome in an efficient way. Recent developments in designer 
endonuclease technologies such as ZFN, TALEN, and CRISPR/Cas9 endonuclease have 
provided ways to significantly improve genome editing efficiency in human iPSCs. Some 
analyses using cancer cell lines reported higher-than-expected levels of off-target 
mutagenesis by Cas9-gRNAs (Fu, 2013; Hsu, 2013), raising concerns about the practical 
applicability of this approach in therapeutic contexts. Some recent studies, including one 
on human adult stem cells, showed a minimal level of off-target effects by CRISPR/Cas9 
(Schwank, 2013). However, these existing analyses of off-target effects and mutational 
load in gene-corrected stem cells have been restricted to checking predicted off target 
sites and are therefore limited in scope. To assess the value of this type of gene editing  
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approach for therapeutic applications, it is critical to rigorously examine whether it is 
possible to generate gene-edited cell lines with minimal mutational load.  
To investigate this we have conducted whole-genome sequencing of four iPSC 
clones successfully targeted at the AAVS1 locus, a ‘‘safe harbor’’ in the human genome 
that is used for stable transgene expression in a variety of contexts. To generate the lines, 
we used an integration-free human iPSC line, BC1, whose genomic integrity has been 
characterized in detail by next-generation sequencing (Cheng, 2012) and targeted a GFP 
expression cassette into the AAVS1 site with either a previously reported Cas9-gRNA 
combination or a pair of improved heterodimeric TALENs (Mali, 2013; Yan, 2013). 
Twenty days after transfection of the donor plasmid and either the TALENs or Cas9-
gRNA into BC1, we harvested four clones with confirmed targeted integration (hCas9-
C4, hCas9-C16, TALEN-C3, and TALEN-C6; Table 2-2) and the parental BC1 iPSCs for 
whole-genome sequencing. 
 
AIM 2 METHODS 
Maintenance and expansion of human iPSCs 
Human iPSCs were cultured with E8 medium (Life Technologies) on tissue 
culture plates coated with Matrigel (BD Biosciences) or Vitronectin (Life Technologies). 
For routine passaging, iPSCs were digested with Accutase (Sigma) for 5 minutes and 
washed with PBS by centrifugation at 200xg for 5 minutes. Digested iPSCs were then 




 with E8 medium supplemented with 10 uM ROCK 
Inhibitor Y-27632 (Stemgent) for the first 24 hours. 
34 
HR-mediated gene targeting at the AAVS1 locus in human iPSCs 
 2 million BC1 iPSCs were nucleofected with either: 1) 5µg AAV-CAGGS-EGFP 
(addgene # 22212), 3µg each of a heterodimeric TALEN pair targeting the AAVS1 (Yan 
2013). 2) 5µg AAV-CAGGS- EGFP (Addgene # 22212), 3µg hCas9 (Addgene #41815), 
and 3µg AAVS1-T2 gRNA (Addgene #41815). Nucleofected cells were plated on 2 
Matrigel coated 6-well plates and were subjected to puromycin selection (0.5 µg/mL) 
from day four to 11 at which point individual colonies were picked and expanded. At day 
20 genomic DNA was isolated and screened for targeted integration (TI) by PCR and 
Sanger sequencing. Clones were also screened for the presence of a wild type allele 
without TI by a PCR amplification using a 30 second extension time insufficient to 
amplify the 3.8-kb TI alleles. 
 
WGS and mutation calling in TALEN vs Cas9/gRNA targeted iPSCs 
Among clones with confirmed targeted integration and lack of random integration 
of donor vector, two were randomly selected for both TALEN and Cas9/gRNA targeted 
iPSCs, and genomic DNA from these clones and the BC1 parental cell line was prepared 
for Illumina sequencing. Sequencing library construction was performed as previously 
described (Gore 2011). Briefly, approximately 1.5 – 3 µg of genomic DNA was purified 
from cells of each sample and sheared with a Covaris AFA. The DNA fragments were 
then end-repaired, A-tailed, and ligated to Illumina barcoded sequencing adaptors. The 
ligated products were amplified by PCR to generate barcoded whole-genome sequencing  
libraries. Each library was pooled together, and the pool was sequenced using two 
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Illumina HiSeq 2000 flowcells (with a variable number of sequencing reads for each 
library based on pooling ratio). 
In order to identify candidate mutations in each edited cell line, variant calling 
was performed as previously described (Gore 2011). Briefly, reads from each flowcell 
were de-barcoded and assigned to each cell line. Reads passing Illumina’s chastity filter 
were mapped to the human reference genome (hg19) using BWA. Clonal duplicate reads 
caused by PCR were then removed using Picard- tools. The remaining nonclonal reads 
were processed as per the GATK Best Practices for small sample sizes, including 
realignment about indels and quality score recalibration. Both SNVs and indel variants 
were then called for each sample using the GATK HaplotypeCaller, with filtering 
parameters based on the GATK Best Practices; additionally, sequencing reads were 
discarded if a single end contributed to more than one SNV or indel. Sites where each 
DNA-edited cell line showed either a heterozygous SNP or an indel call that was not 
observed in the unedited cell line were considered as mutations if at least 30% of reads in 
the edited cell line contained the mutation, no allelic content derived from the mutation 
was present in the unedited line, and if the candidate mutation had not previously been 







AIM 2 RESULTS 
CRISPR/Cas9 or TALEN stimulated KI to the AAVS1 safe harbor locus 
When comparing total number of puromycin resistant colonies CRISPR/Cas9 had 
a two-fold advantage but both were equivalent in their 100% targeting efficiency, of all 
28 puromycin resistant iPSC clones screened had the intended AAVS1 KI by PCR. 
Candidates for targeted integration were then confirmed by Sanger sequencing of the 5’ 
and 3’ juntions. iPSC clones with single allele AAVS1 KI were screened for by the 
presence of untargeted wild type band using a short extension time to avoid the 4.5kb 
product from the targeted integration. TALEN and Cas9 were equivalent in the rate of bi-
allelic integration at about ~33% of clones analyzed. Among the majority of clones with 
single allele integration the other allele was sequenced to screen for indel mutations 
caused by NHEJ. None of the TALEN single-allele targeted clones (0 of 6) contained a 
mutation on the other allele while 50% (3 of 6) Cas9 targeted mutations contained indels. 
Although all the screened iPSC clones had the targeted AAVS1 KI but additional random 
integration of the donor vector at other genomic loci was screened for using a PCR 
strategy unique to the donor vector but outside the homology arms and intended 
integration. Random integration was high in both Cas9 and TALEN at ~65% removing 
most candidate clones from further characterization. Combining all these screening 
criteria two top candidates for each TALEN and Cas9 targeted clones were selected along 
with parental BC1 iPSCs for WGS. 
 
37 
Figure 2-1 AAVS1 targeting diagram, timeline, and screening strategy. (a) Timeline 
of gene targeting in BC1 iPSCs and genomic DNA isolation for sequencing. BC1 iPSCs 
were co-nucleofected by a donor plasmid AAV-CAGGS-EGFP with either TALENs or 
Cas9-gRNA.  Nucleofected cells were cultured at a low density for four days before 
puromycin selection.  Individual puromycin-resistant clones picked at day 11 were 
further expanded for additional nine days. Genomic DNAs isolated at day-20 were used 
for analyses of targeted integration event and for whole genome sequencing. (b) 
Diagrams of the donor plasmid AAV-CAGGS-EGFP, the native AAVS1 (PPP1R12C) 
locus structure and the genomic structure after targeted integration of GFP expression 
cassette (GFP KI). Primers for PCR amplification of targeted allele (red), untargeted 
allele (blue) and random integration (purple) were shown. DNA probe (5’ probe) for 
southern analysis of SphI (S) digested genomic DNA were also indicated. The HR-
mediated targeted integration at AAVS1 by TALENs and Cas9-gRNA. 2x10
6
 BC1 iPSCs 
were used for each experiment. Puromycin-resistant iPSC clones were randomly picked, 










parental iPSCs to enable the generation of a list of potential variations arising during the 
gene editing process, which we then confirmed using genomic PCR and Sanger 
sequencing. We confirmed 62 out of 69 SNVs tested for an overall confirmation rate of 
90%, and based on that we estimate that the total SNVs in the four iPSC clones range 
between 217 and 281 and that the total indels range between 7 and 12 (Table 2-2). 
Overall the genomic variation levels in TALEN- and Cas9-targeted groups were 
comparable. 
 
No SNVs or indels were recurrent or similar their respective nuclease binding sites. 
 One important consideration is how many of these detected SNVs and indels were 
the results of off-target mutagenesis by the engineered endonucleases. To address this 
question, we generated a list of 3,665 (Cas9) and 238 (TALEN) putative off-target 
positions by using the EMBOSS fuzznuc software package. Each candidate SNV and 
indel was compared to this list and none of them are within a potential off-target region 
(Table 2-2), consistent with previous analyses looking at predicted off-target sites. Our 
analysis also shows that each SNV and indel is unique and that none of them occurred in 
more than one cell line. The absence of recurring mutations and the fact that none of the 
mutations resides in any putative off-target site by bioinformatic prediction strongly 
suggest that these mutations were randomly accumulated during regular cell expansion 






Figure 2-2 Genome editing timeline for clonal isolation of targeted iPSCs. BC1 
parental iPSCs were transfected with AAV-CAGGS-EGFP (HDR donor vector) and 
either: 1) AAVS1-TALEN-L + AAVS1-TALEN-R or 2) Cas9 + gRNA-AAVS1-T2 and 
plated at low density (2 x 6 well plates) for clonal isolation. Puromycin selection was 
started at day 4 and continued throughout the clonal isolation process. At day 11 colonies 
were manually picked and expanded individually for genomic DNA extraction and 
continued culture. 
Table 2-1 WGS summary of TALEN vs Cas9 targeted iPSCs 
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Figure 2-3 Southern blot confirms targeted integration into the AAVS1 safe harbor 
locus. Southern blot analysis was performed on selected iPSC clones that were positive 
for a targeted event (TI) and were negative for random integration based on PCR 
screenings.  Using the DNA probe shown in Figure 2-1a, hybridization to DNA with 
targeted integration would result in 3.8 kb band while un-targeted DNA would result in 
6.5 kb band. Four targeted iPSC clones (hCas9-C4, C16 and TALEN-C3, C6) were 





Figure 2-4 WGS alignment, variant calling, and analysis pipeline screening for off-
target mutagenesis. After confirming 2 TALEN and 2 Cas9 successfully edited iPSCs 
genomic DNA was used for sequencing using the illumina HiSeq 2000 to generate ~30x 
coverage. These reads were then aligned to the reference genome (hg19) using BWA and 
variants were called using GATK with local re-alignment for indel analysis. To 
investigate mutations acquired during the genome editing process all variants found in the 
parental BC1 iPSCs were excluded from each of the targeted clones. All new mutations 
were screened for similarity to the nuclease binding site (within 100 bps) up to 5 
mismatches from the gRNA or TALEN sequence. Recurrent mutations were also 
searched for among all the targeted clones for signs of rare variants found in the parental 
iPSCs or a non-sequence based off-target site. 
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AIM 2 DISCUSSION 
To fully utilize iPSCs for disease modeling or regenerative medicine requires the 
ability to precisely modify these cells without inducing undesired off-target mutagenesis 
that would confound results or could lead to oncogenic transformation. Many approaches 
have been taken by others such as targeted amplicons sequencing of predicted off-target 
loci, or target capture to enrich for DNA at these sites but an unbiased approach to search 
genome wide for mutagenesis was lacking to fully investigate the genomic integrity after 
gene targeting combined with designer nucleases. When comparing overall efficiencies 
of targeted integration at the AAVS1 locus Cas9 had a two fold advantage of TALEN but 
both generated more colonies than could be picked. For this experiment only single allele 
targeted clones were selected for further analysis and the untargeted allele was screened 
for indels caused by NHEJ from the nuclease; confirming previous work in aim one Cas9 
leads to more frequent disruption of the other allele, found in 50% of clones, while 
TALEN targeted clones were all wild-type at the untargeted allele.  
In the previous aim based on previous deep sequencing of predicted off-target loci 
conducted in aim one only a single locus showed significant off-target cleavage (OT-5, 
chr13:106612912) in the bulk transfected cells but was only slightly elevated over the 
background mutation rate; this site was not mutated in any of the sequenced clones. All 
sites in the genome within five mismatches to the nuclease binding site were also 
screened but no mutations were identified in all clones screened indicating that for these 
gRNA and TALEN genome edited clones can readily be derived with no evidence for 
off-target mutagenesis at sites of similar sequence.  
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These results from whole-genome sequencing analysis of Cas9- and TALEN-
targeted human iPSC clones demonstrate that these engineered endonucleases provide 
efficient genome-editing tools with high specificity. It remains to be clarified whether the 
higher off-target rates observed in cancer cell lines are due to the overexpression of 
gRNAs and Cas9 protein and/or due to exacerbated and faulty DNA repair in these cell 
types. The higher specificity observed in human iPSCs, combined with the rapid 
development of next-generation sequencing technology, makes it possible to characterize 
and isolate high quality genome-edited stem cell clones with minimal mutational load. 
The guiding principle established with human iPSCs will likely be applicable to other 
types of stem cells and come with improvements in gene transfer and targeting 
efficiencies. Our current study of gene targeting in human iPSCs will help to establish 
better models for human biology and disease research and to provide proof-of-principle 




















Aim 3: Knockout the PEAR1 gene and its cis-regulatory 




Genetic variation within platelet endothelial aggregation receptor 1 (PEAR1) has 
been associated with platelet aggregation and was later reported to act as a negative 
regulator of cell proliferation and lineage commitment during megakaryopoiesis. To 
investigate this a PEAR1 KO iPSC line was generated that resulted in a homozygous 
frameshift mutation that ablated PEAR1 expression during iPSC derived megakaryocyte 
differentiation. When compared to otherwise isogenic iPSCs, PEAR1 KO iPSCs 
displayed accelerated megakaryocyte lineage commitment during hematopoietic 
differentiation as measured by cell surface expression of CD41 and CD42 which was 
accompanied by an increased cell proliferation which continued through megakaryocyte 
differentiation. PEAR1 cell surface expression naturally increased over the course of 
hematopoietic and megakaryocyte differentiation but these results indicate that it is not 
essential for their proper maturation and acts as a negative regulator of cell growth during 
the process. A SNP (rs12041331) within the first intron of PEAR1 was reported to reside 
within an enhancer by a luciferase assay while more investigation is required to elucidate 
its role in the native chromatin context of an appropriate cell type. BC1 cisPEAR1 KO 
was created with a 251 bp single allele deletion containing rs12041331, leaving the other  
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allele unmodified by Cas9. When this clone was compared to parental BC1 iPSCs PEAR1 
mRNA expression was reduced ~50% during hematopoietic differentiation and ~30% 
during megakaryocyte differentiation demonstrating regulatory effects of this region on 
gene expression. Further analysis of BC1 cisPEAR1 KO mRNA revealed that the 
reduction in expression was primarily on the same allele as the deletion, indicating a cis-
regulatory mechanism of action for the region containing rs12041331. 
 
AIM 3 INTRODUCTION 
Proper production, activation, and aggregation of platelets play a critical role in 
normal human hemostasis as well as many states of disease including arterial thrombosis, 
atherosclerosis and thrombocytopenia. The production of platelets begins in the bone 
marrow where hematopoietic stem cells divide asymmetrically leading some of their 
progeny towards the common lymphoid progenitor (CLP) destined for lymphocytes and 
NK cells, while others are directed towards the common myeloid progenitor (CMP) 
which gives rise to granulocytes, monocytes, erythrocytes, and platelets. The CMP 
further differentiates to a megakaryocyte/erythroid progenitor (MEP) that remains 
bipotent with the capacity for red blood cells and platelets until TPO directs their 
commitment towards the megakaryocyte progenitor which undergoes a complex process 
of membrane restructuring, protein production and packaging coupled with endomitosis, 
a process of nuclear division without cell division, resulting in large polynucleated 
megakaryocytes that shear into proplatelets and are ultimately released as mature 
platelets from the vascular sinusoids in the bone marrow into the blood stream. Mature  
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platelets lack a nucleus but they retain their endoplasmic reticulum which aids in 
maintaining an inhibited resting state until exogenous agonists such as ADP, collagen or 
thrombin are detected and lead to activation. Integrin αIIbβ3, also known as glycoprotein 
IIb/IIIa, is a key membrane bound receptor that is tightly repressed during normal platelet 
function. Platelet activation leads to a conformational change in Integrin αIIbβ3 exposing 
its receptor domain allowing fibrinogen or von Willebrand factor to bind, causing 
sustained platelet-platelet contacts from crosslinking and coagulation and the formation 
of platelet plugs. Activated platelets create a positive feedback loop recruiting and 
activating adjacent platelets by releasing ADP, fibrinogen and other factors such as stored 
α-granules and dense-granules upon activation. 
Platelet Endothelial Aggregation Receptor 1 (PEAR1) was initially identified 
during a proteomic analysis of platelet proteins that undergo post-translational 
modification in response to platelet activation. Protein domain analysis revealed PEAR1 
contains 15 extracellular epidermal like growth factor (EGF) repeats, an EMI protein-
protein interaction domain and an intracellular tyrosine (Tyr-925) that becomes 
phosphorylated upon platelet contact by centrifugation, or by activation by delivery of an 
agonist which could be blocked by an inhibitor of the integrin αIIbβ3 pathway (Nanda et 
al., 2005). Further tissue expression analysis by the same group revealed that in addition 
to platelets, PEAR1 is also expressed in endothelial cells, megakaryocytes, erythroid 
cells, and at low levels in several other cells types.  At this point it is clear that PEAR1 
plays a role in signal transduction of platelets and/or endothelial cells but the function  
of PEAR1 phosphorylation was still unknown at this time.  
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A GWAS investigating platelet aggregation phenotype identified a PEAR1 
intronic SNP, rs12041331 (A/G) that was associated with platelet aggregation phenotype 
as measured by agonist induction using collage, ADP, or epinephrine. The major variant 
G, was associated with greater platelet aggregation as well as increased protein content in 
blood derived platelets (Faraday et al. 2011). To address how intronic genetic variation 
may influence protein levels rs12041331 was tested for cis-regulatory potential by 
luciferase assay and found to act as an enhancer while the G variant construct increased 
expression significantly greater than the A variant. Another independent GWAS linked 
rs12041331 to platelet aggregation phenotype again with the major variant G associated 
with greater platelet aggregation, but surprisingly the A variants was associated with 
increased risk of adverse cardiovascular disease outcomes (Lewis et al. 2013). Normally 
increased platelet aggregation is a risk factor for adverse clinical outcomes including 
heart attack and stroke but rs12041331 seems to have opposite effects with regards to 
these two phenotypes. These paradoxical findings promote further investigation into the 
role of PEAR1 function in megakaryopoiesis and its potential regulation by genetic 
variation within the first intron. 
Functional characterization revealed that the extracellular domain of PEAR1 
binds platelets while the intracellular domain becomes phosphorylated and signals 
through the PI3K/AKT pathway that leads to activation of integrin αIIbβ3 revealing a 
functional mechanism to explain the previously reported GWAS hit (Kauskot et al. 
2012). The initial studies implicated a functional biological and molecular role for this 
protein at the final platelet stage but experiments evaluating megakaryopoiesis revealed a  
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functional role of PEAR1 in cell lineage commitment and growth. When PEAR1 was 
knocked down using siRNA in human CD34
+
 cells purified from peripheral blood it 
resulted in increased megakaryocyte lineage commitment as observed by increased 
numbers of CFU-MK without influencing CFU-E. Upon in vitro megakaryocyte 
differentiation PEAR1 knockdown increased cell proliferation but did not inhibit final 
maturation characteristics including cell surface expression of CD41 and CD42 double 
positive cells, and production of 4N and 8N polyploidy cells, concluding that it is an 
attenuator of megakaryopoiesis without disrupting the production of mature 
megakaryocytes (Kauskot et al. 2013).  
This stage of development is better suited for disease modeling in iPSCs as there 
are defined protocols for hematopoietic and megakaryocyte differentiation while defined 
techniques for iPSC-derived functional platelets are lacking. In this study CRISPR/Cas9 
was used to KO PEAR1 in health iPSCs to compare its effect on megakaryopoiesis when 
differentiated alongside the parental iPSCs they were derived from. Megakaryocyte 
development was monitored by expression of integrin, CD41, and glycoprotein 1b, CD42 
during the differentiation process. To investigate the regulation and timing of PEAR1 
expression during hematopoiesis and megakaryopoiesis rs12041331 was deleted using 
two gRNAs spaced 251 bp apart flanking this SNP to disrupt the putative enhancer in 
which it resides. BC1 cisPEAR1 KO iPSC line was isolated with a single allele targeted 
deletion and compared to otherwise isogenic BC1 parental iPSCs by qRT-PCR for 
relative PEAR1 mRNA analysis. Cis-regulatory effects were isolated by sequencing exon 
8 of PEAR1 mRNA, which contains an unrelated SNP, rs7723503 (A/C), used quantify  
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the relative expression from the wild type allele to the allele containing the intronic 
deletion. Initial reports that genetic variation within PEAR1 is associated with platelet 
aggregation phenotype as well as adverse clinical outcomes warrants further investigation 
into its role and regulation during megakaryopoiesis using genome editing in iPSCs to 
model these PEAR1 alterations in isolation.  
 
AIM 3 METHODS 
Human iPSC based hematopoietic and megakaryocyte differentiation 
BC1 iPSCs were grown on Vitronectin coated plated with Essential 8 media 
media and passaged by accutase for single cell digestion. Spin-Embryoid Body (EB) 
hematopoietic differentiation followed by five days of megakaryocyte differentiation was 
carried out as previously described (Liu et al. 2015) to compare genome edited lines to 
the parental BC1 iPSCs from which they were derived. At day 12 a 70 µm filter was 
applied to remove the bulk EB cells from the suspension cells containing the 
hematopoietic stem and progenitor cells (HSPCs) which were counted using the countess 
to determine total cell number and divide 3 x 10
5
 cells for each sample of FACS, 1 x 10
6
 
for RNA extraction, and 3 x 10
6
 cells for continued megakaryocyte differentiation. FACS 
analysis was conducted for hematopoeitc markers (CD34 and CD45), megakaryocyte 
markers (CD41 and CD42) and for PEAR1 expression. After five days of megakaryocyte 




Genome editing PEAR1: coding sequence (Exon 6) and rs12041331 KO 
Two gRNAs (P1E6a and P1E6b) were designed to target PEAR1 exon 6 because 
this exon was present in also isoforms past their transcription start site. They were spaced 
173 bp apart to increase the chance of an out of frame deletion as the common breakpoint 
occurs three nucleotides upstream of the PAM. To delete rs12041331 several 
combinations of gRNAs were designed and tested in HEK293T cells but only the most 
efficient pair, gRNA-Dg1 and gRNA-P1g1A, were used to target BC1 iPSCs. 2 million 
BC1 iPSCs were nucleofected as previously described (Smith et al. 2015) with 3 µg of 
each of gRNA and 9 µg of pCas9_GFP. Cells were enriched for pCas9_GFP+ cells by 
FACS and plated at low density (50-200 cells per 6-well) for clonal isolation and 
screening of PEAR1 target. An additional round of low density seeding and colony 
picking was repeated to ensure that cells were clonal. 
 
mRNA extraction, cDNA conversion and RT-PCR  
In parallel with FACS analysis and DNA isolation to genotype ensure the 
samples, RNA was extracted from ~1 million cells using the Zymo RNA isolation Kit 
which removes genomic DNA in two steps including a filter and enzymatic DNase 
removal. 300 ng – 1µg of total RNA was used as a template for cDNA synthesis was 
conducted with the Superscript III (Life Technologies) using random hexamers by the 
manufacturers recommended protocol. RT-PCR for PEAR1 was conducted using the 
following primers: E8P1F (5’-CAAAATGGAGGTGTCTTCCAA) and E8P1R (5’-
ACCGATCCCCAGTGTAACC) using the SYBR green master mix using CT method 
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and normalizing each sample to GAPDH. All samples were further normalized to the 
average of BC1 iPSC derived HSPCs over three biological replicates to compare the MK 
and bulk EB time points. 
 
Deep sequencing for allele specific analysis of PEAR1 exon 8 
 Starting with cDNA from each cell line (BC1 and BC1 cisPEAR1 KO) and time 
point (EB day 12, MK day 5) DNA barcoded primers were used to amplify PEAR1 exon 
7 and 8 containing a SNP rs77235035 (A/C) for three biological replicates of each sample 
conducted at independent differentiation experiments. PCR amplicons were purified 
using the QIAGEN PCR purification kit and quantified using Qubit dsDNA BR Assay 
kit. 125 ng of each sample was pooled together, mixed for KAPA library preparation kit 
(Product # KK8234) for deep sequencing on the MiSeq v2 2x250 sequencing chemistry. 
After confirming quality, length and throughput of reads using FastQC, reads were 
demultiplexed using the ea-utils fastq-multx function from both the forward and reverse 
strands. Each sample was the aligned to the reference sequence for the spliced form of 
PEAR1 exon 7 and 8 and extracted the total nucleotide counts for the position of 
rs77235035 to compare allelic mRNA expression. The percentage of reads for each allele 






AIM 3 RESULTS 
An iPSC based model to generate PEAR1 expressing megakaryocytes. 
BC1 iPSCs were used as a normal control to test if our iPSC based model to 
produce HSPCs and megakaryocytes for PEAR1 expression as well as megakaryocyte 
lineage markers CD41 and CD42. At day 12 of spin-EB hematopoietic differentiation 
PEAR1 surface expression was detected on ~25% of cells and CD41+CD42+ double 
positive cells made up about ~20% of the population (Figure 3-1) indicating that a 
population of megakaryocyte precursors already exists at this stage before specific 
megakaryocyte induction. Megakaryocyte differentiation was continued for five days 
with PEAR1 expression reaching 80% while CD41+CD42+ cells reached ~75% 
indicating a successful megakaryocyte maturation that could be used to further 
interrogate PEAR1 function from this iPSC based model. 
 
173bp deletion induces a frame shift in PEAR1 ablating cell surface expression. 
PEAR1 KO iPSCs were created using two gRNAs, gRNA-P1E6a and gRNA-P1E6b, to 
induce a 173 bp deletion leading to a premature termination codon before the 
transmembrane domain (Figure 3-2). After FACS enrichment for Cas9_GFP+ iPSCs cells 
were seeded at low density for isolation of individual colonies of which 6/12 screened 
contained the deletion a remarkable improvement over unsorted cells. After clonal 
isolation through two rounds of serial dilution, BC1 PEAR1 KO clones were isolated and 
a single clone was used for functional studies. Bi-allelic deletion was suspected due to the 




Figure 3-1 An iPSC-based model to generate PEAR1 expressing megakaryocytes. 
BC1 iPSCs were used for the spin-EB mesoderm differentiation protocol to produce 
hematopoietic stem and progenitor cells (HSPCs) after 12 days of culture. These HSPCs 
were found to express PEAR1 at ~25% as detected by FACS and were ~75% double 
positive for CD41 and CD42, lineage markers for megakaryocytes and their precursors. 
By day 5 of megakaryocyte differentiation the cells typically become quite large after 





both alleles of a SNV, rs735953 (T/C), within the sequenced products. By bacterial 
transformation and colony picking each allele could be sequenced individually revealing 
the same deletion with breakpoints at the third nucleotide 5’ of the PAM sequence for 
each gRNA present on both the T and the C containing alleles. PEAR1 KO iPSCs 
maintained their capacity for hematopoietic differentiation as observed from the release 





positive cells but had no detectable PEAR1 protein expression at any time point (Figure 
3-3). To evaluate mRNA expression of PEAR1 during differentiation qRT-PCR was used 
for PEAR1 that revealed a 50% reduction in mRNA levels at the iPSC-HSPC stage while 
a 20% reduction was observed at the iPSC-MK final time point. This indicates that non-
sense mediated decay (NMD) or some other mechanism is reducing mRNA levels of the 












Figure 3-2 Homozygous PEAR1 KO achieved in BC1 iPSCs. (a) PEAR1 is depicted 
with exons as boxes and introns as lines with a zoom in on exon 6 for targeted disruption 
with PCR screening primers shown in purple to generate a 492bp band. Two gRNAs 
indicated by red dotted lines are spaced 173bp apart within exon 6 (P1E6a and P1E6b). 
(b) Gel results for E6del PCR showing BC1 iPSCs with the wt 492bp band and BC1 
PEAR1 KO a single band the size of anticipated deletion indicating a homozygous 
deletion. (c) Expected deletion product size after cleavage at both gRNAs yielding a 319 
bp band. The unrelated SNP, rs735953 is used to screen the mutation status of each allele 
after clonal sequencing. (d) The reference sequence is displayed with gRNA sequences in 
green boxes followed by their protospacer adjacent motif (PAM) in yellow. Both alleles 
in BC1 PEAR1 KO had the same 173bp deletion starting at the third nucleotide upstream 












Figure 3-2 Homozygous PEAR1 KO achieved in BC1 iPSCs.
 
 
PEAR1 KO accelerates megakaryocyte lineage commitment and cell growth during 
iPSC-based differentiation. 
During hematopoietic differentiation PEAR1 KO iPSCs displayed an accelerated 





 double positive cells when compared to parental iPSCs (Figure 3-5). 
Hematopoietic lineage markers, CD34 and CD45, were not significantly altered 
indicating successful blood differentiation was not disrupted in either population. A cell 
growth phenotype was also observed with a 2.5 fold increased total number of suspension 
cells harvested from PEAR1 KO iPSCs when compared with parental cells indicating that 
PEAR1 acts as a negative regulator of growth during hematopoiesis (Figure 3-4). It was  
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also observed that release of hematopoietic suspension cells from the embryoid body 
occurred ~1 day earlier in PEAR1 KO iPSCs when compared to BC1 parental cells. After 
5 days of growth under conditions to promote megakaryocyte differentiation BC1 
PEAR1 KO iPSCs continued to have a cell growth advantage when compared with 





double positive cells in addition to the characteristic cell enlargement indicating a 




















Figure 3-3 BC1 PEAR1 KO ablated PEAR1 protein expression. (a) A representation 
of spin-EB hematopoietic differentiation comparing BC1 iPSCs to BC1 PEAR1 KO 
iPSCs. Cells are analyzed by isolating suspension cells from the bulk EB at day 12 
containing the hematopoietic stem and progenitor (HSPC) which are further 
differentiated and megakaryocyte stages. (b) FACS analysis of HSPCs and MKs display 
PEAR1 expression on the x-axis by SSC and show the PEAR1 KO iPSC ablated PEAR1 





Figure 3-4 PEAR1 KO increased hematopoietic growth. There was a clear growth 
advantage from the PEAR1 KO when compared to BC1 iPSCs from which they were 
derived as seen in the early emergence of suspension cells containing the hematopoietic 
progenitor. A graph of the cell number harvested on day 12 by filtering the bulk EB to 
only count and analyze cells less than 70 µm used for FACS and continued 
megakaryocyte differentiation. Data represents an average of three biological replicates 
of indepenedent differentiation experiments, error bar represents SEM. After 5 days of 
growth in megakaryocyte inducing media large cells could be observed under the 
microscope in both BC1 and PEAR1 KO iPSC derived megakaryocytes. Cells were 
counted at day 2, and 4 when changing media and on day 5 when they were analyzed by 





Figure 3-5 PEAR1 KO accelerated megakaryocyte lineage commitment. (a) iPSC 
derived HSPCs and MKs from either BC1 parental iPSCs or PEAR1 KO were screened 
by FACS and the CD41+CD42+ double positive cells were plotted. Data represents an 
average of three biological replicates of independent differentiation experiments, error 
bar represents SEM. (b) FACS plot displaying CD41 on the Y-axis and CD42 on the X-
axis. A clear double positive population is observed in PEAR1 KO that is not seen in 









Figure 3-6 Epigenetic landscape of PEAR1 around rs12041331. Data viewed in 
UCSC genome browser covering the PEAR1 intron 1 shown on the top track. P1del 
represents the deletion size of gRNAs covering rs12041331 marked on the following 
track. Orange tracks below represent human umbilical vein endothelial cells (HUVEC) 
followed by H1 human embryonic stem cells (hESC). DNase hypersensitivity tracks from 







BC1 cisPEAR1 KO increased cell proliferation during hematopoietic 
differentiation. 
 After confirming a functional role for PEAR1 in iPSC derived megakaryopoiesis 
the regulation of this gene became the target of further study. Genetic variation within the 
first intron of PEAR1 showed cis-regulatory potential by the luciferase assay but further 
characterization of this element in its endogenous genomic context was necessary to 
elucidate its role in regulation during megakaryopoiesis. To address this BC1 cisPEAR1 
KO was generated using two gRNAs to cause a 251 bp single allele deletion of region 
surrounding rs12041331, leaving the other allele unmodified by Cas9 (Figure 3-7). Both 
alleles were isolated by TOPO cloning and sequenced to determine the exact breakpoint 
and confirm that no mutations occurred on the wild type allele by either gRNA. When 
BC1 cisPEAR1 KO was compared to parental BC1 iPSCs, there was a growth advantage 
during hematopoiesis and megakaryopoiesis (Figure 3-8). The megakaryocyte progenitor 




 double positive cells was slightly but not 
significantly elevated in iPSC-HSPCs in cisPEAR1 (Figure 3-9) unlike the full PEAR1 
KO experiments. Additionally when PEAR1 protein was analyzed by FACS the 










Figure 3-7 Generating cisPEAR1 KO: a deletion of rs12041331 within a putative 
enhancer. (a) The PEAR1 gene is displayed with rs12041331 (A/G) within the first 
intron expanded for the PCR product used for screening targeted clones. gRNAs (P1g1A 
and Dg1) are shown as green lines with yellow caps for the PAM sequences. BC1 
cisPEAR1 KO is shown below with a wild-type allele containing rs12041331 that is not 
mutated and the other allele containing a deletion covering this SNP. (b) Independent 
sequencing of each allele showed a 251 bp deletion that started at the third nucleotide 
upstream of the PAM for each gRNA. The full length allele was shown to harbor no 







Figure 3-8 cisPEAR1 KO showed increased cell proliferation during hematopoietic 
differentiation. (a) Schematic of spin-EB hematopoietic differentiation followed by 
megakaryocyte maturation comparing the cisPEAR1 KO clone and the BC1 iPSCs that it 
was derived from (b) Cell growth determined by counting suspension (countess) cells 
after EB day 12 and counting total cell number during megakaryocyte differentiation. 
The robust growth phenotype was largely observed in the generation of HSPCs but only a 








Figure 3-9 Expression of megakaryocyte markers were not significantly elevated in 
cisPEAR1 KO. (a) Percentage of CD41+CD42+ double positive cells as determined by 
FACS at the HSPC stage and megakaryocyte stage comparing BC1 iPSCs to cisPEAR1 
KO. Data represents the mean of three biological replicates with errors bars shown as 
SEM. (b) FACS plot with CD41 on the Y-axis and CD42 and on X-axis. While the 
overall percentage was slightly but not significantly elevated the plot shows a 







Figure 3-10 cisPEAR1 KO did not affect PEAR1 surface expression. (a) Percentage 
of PEAR1 expression cells as measure by FACS, the mean of 3 experiments with error 
bars plotted as SEM. (b) FACS plot measuring SSC on the Y-axis and PEAR1 on the X-
axis. When compared to parental BC1 iPSCs, cisPEAR1 KO did not affect PEAR1 cell 
surface protein expression. 
 
Deletion of rs12041331 decreased mRNA expression of PEAR1 on the same allele as  
the deletion, indicating that it resides within a cis-regulatory element. 
When comparing cisPEAR1 KO iPSCs to the BC1 iPSCs that they were derived 
from PEAR1 mRNA expression was reduced by ~50% during hematopoietic 
differentiation and ~30% during megakaryocyte differentiation over three biological  
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replicates as analyzed by qRT-PCR confirming its regulatory effects during 
hematopoiesis and megakaryopoiesis (Figure 3-11). Although a decrease in mRNA 
expression was found in all hematopoietic derived cells, endothelial cells are also of 
interest as they are known to express PEAR1 and are found in the bulk EB before the 
hematopoietic suspension cells are released. When bulk EB cells were analyzed after 
removing all free cells with a 70 µm filter PEAR expression was quantified using qRT-
PCR and found to express PEAR1 ~50 fold greater than HSPCs (Figure 3-12). 
Interestingly there was no significant difference in PEAR1 expression between BC1 and 
cisPEAR1 KO in the bulk EB cells indicating that this enhancer is cell type specific and 
does not influence gene expression in this higher expressing mix of cell types that make 
up the EB. 
To determine if the reduction in mRNA was occurring on the same allele as the 
enhancer deletion a naturally occurring unrelated SNP, rs77235035 (C/A), within exon 8 
was utilized to monitor the ratio of PEAR1 expression from each allele. The linkage of 
the intronic SNP of interest rs12041331 was linked to exon 8 by long range PCR which 
was TOPO cloned and sequenced to isolate each allele. Total mRNA extracted from BC1 
iPSCs during differentiation was first converted to cDNA then PCR amplified around 
spliced exon 8 and sequenced resulting in 79.5% of reads contained the A allele 
indicating a baseline bias that influences PEAR1 expression from a specific allele in 
iPSC-HSPCs and Megakaryocytes (Figure 3-13). As BC1 is homozygous AA for 
rs12041331 there is likely other regulatory elements that are influencing PEAR1 
expression in an allele specific manor that are not identified or covered in this study. 
69 
When BC1 cisPEAR1 KO mRNA was analyzed from iPSC-derived HSPCs the A allele 
was only present in 32.0% of the reads sequenced indicating the reduction of total mRNA 
is primarily occurring on the same allele as the intronic deletion suggesting a cis-
regulatory mechanism of action for this element at this stage of development. Upon 
analyzing iPSC-derived megakaryocytes from BC1 cisPEAR1 KO the A allele was 




Figure 3-11 PEAR1 total mRNA levels were reduced during differentiation in 
cisPEAR1 KO. Cell pellets were harvested from both BC1 and cisPEAR1 KO at the 
HSPC and Megakaryocyte time points for RNA extraction, and cDNA conversion for 
quantitative RT-PCR. Expression was normalized to GAPDH for each sample and 
normalized to BC1 HSPCs to a level of one for comparison across all samples. A 50% 
reduction was observed at both the HSPC and the MK time points but more variation was 
observed in the megakaryocytes. Data displayed is the mean of three biological replicates 




Figure 3-12 PEAR1 mRNA levels were not reduced in bulk embryoid body cells 
derived from cisPEAR1 KO. At day 12 of spin-EB hematopoietic differentiation the 
suspension cells were harvested using a 70 µm filter while the cellular material not 
filtered was collected for bulk EB analysis. RT-PCR was conducted as previously 
described to reveal an overall higher level of expression of PEAR1 in the bulk EB cells 
when compared to hematopoietic derived cells. Additionally the cisPEAR1 KO did not 
show reduced PEAR1 expression in the bulk cells but only the HSPCs and MKs 








Figure 3-13 cisPEAR1 KO decreased PEAR1 mRNA on the same allele as the 
deletion.  (a) PEAR1 genetic variation is displayed from the IGV genome browser 
showing BC1 genetic variation from the reference. BC1 is homozygous A for 
rs12041331, key SNP for this study but an unrelated SNP, rs77235035, within exon 8 
was used to monitor allelic expression of PEAR1. Using long range PCR both BC1 
iPSCs and cisPEAR1 KO were sequenced to determine the linkage group for each allele. 
“Allele 2” for BC1 cisPEAR1 KO is monitored by the A allele of Exon 8. (b) Plots 
displaying the percentage of “allele 2” (A) reads from mRNA divided by the total reads 
for BC1 and cisPEAR1 KO from three independent transfections, error bars are SEM. 
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AIM 3 DISCUSSION 
The proper biosynthesis and functionality of platelets is integral to hemostasis, 
wound recovery and is involved in many complex diseases such as atherosclerosis. 
GWAS have identified a plethora of variants for a wide range of human phenotypes and 
diseases but proper identification of the causal variant and functional follow up studies 
are often lacking or missing all together. While increasing the cohort size will reveal 
variants of smaller effect, multigenic or gene environment interactions may be impossible 
to discern using this purely statistical method. With the rapid increases in precise genome 
editing it is now feasible to alter these variants of interest and evaluate their effects in 
isolation or under certain controlled conditions such as differentiation or chemical 
induction. These results demonstrate the feasibility for CRISPR/Cas9 based genome 
editing techniques to either disrupt a protein coding gene or putative cis-regulatory 
element associated with biological phenotype to discern its cellular and molecular effects. 
This study first showed that an iPSC based model of hematopoiesis and 
megakaryopoiesis mirrors biological development in the proper timing and expression of 
PEAR1 and the megakaryocyte lineage markers CD41 and CD42; a requirement to 
investigate PEAR1 function in this in vitro system. This differentiation model provided 
an ideal environment to KO PEAR1 and its putative enhancer containing the SNP 
rs12041331 to interrogate their effects on megakaryopoiesis or PEAR1 mRNA and 
protein expression. The first major results confirm PEAR1 as a non-essential negative 
regulator of megakaryopoiesis as a cell growth advantage was observed in BC1 PEAR1 
KO when compared with otherwise isogenic parental controls but production of mature  
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megakaryocytes was not disrupted. This was not surprising as PEAR1 was shown to 
signal through the PI3K/AKT pathway, which is known to regulate cell proliferation and 
was previously reported to negatively influence cell growth in human CD34
+
 peripheral 
blood cells during megakaryocyte differentiation (Kauskot et al. 2013). While these 
observations are in concordance with the Kasuskot study, an iPSC based approach also 
undergoes mesoderm lineage commitment to produce the HSPCs necessary for 
megakaryocyte differentiation, an earlier stage in development than the previous studies 
using peripheral blood derived CD34
+
 cells. A cell proliferation advantage was also 
observed during this early hematopoietic differentiation indicating PEAR1 influences 
commitment and or cell proliferation at an earlier stage in development than previously 
reported. While previous investigation into the function PEAR1 and its regulation relied 
on synthetic reporter constructs or siRNA knockdown approaches this study used 
CRISPR/Cas9 guided deletion determine the role that this gene and its putative enhancer 
play in the regulation megakaryopoiesis.  
After probing the role of the PEAR1 gene by coding sequence KO the next 
objective of this aim was to follow-up on the putative enhancer within its first intron 
containing the SNP rs12041331. Previous studies provided several lines of evidence that 
this region was acting as a regulatory of gene expression from peripheral blood analysis 
as well as luciferase assay, but has not been replicated since (Faraday 2011). By deleting 
251 bp containing rs12041331 an overall reduction in mRNA levels was observed in both 
iPSC derived HSPCs and megakaryocytes confirming the previous observations but in 
the endogenous chromatin context of iPSCs differentiated to the relevant cell type. In the 
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bulk EB total mRNA levels were ~50 x higher which corroborates previous reports that 
endothelial cells express PEAR1 at orders of magnitude higher levels than hematopoietic 
derived cells (Nanda et al. 2005) but interestingly the levels of PEAR1 expression in the 
cisPEAR1 KO clone was not reduced in this cell type but only in the hematopoietic 
lineages. This reveals the regulatory potential of this region on the PEAR1 gene within 
which it resides in a cell type specific manor but from totals mRNA levels a cis-acting 
mechanism of regulation cannot be distinguished from other indirect mechanisms of gene 
regulation that might act on both alleles equally. By deep sequencing mRNA from 
HSPCs and MKs derived from BC1 iPSCs it was determined that the exon 8 variant A for 
rs77235035, allele 2, was expressed four times greater than the C containing allele 1 
(Figure 3-13). This indicates a pre-existing bias in allelic expression and as BC1 is 
homozygous for rs12041331, there is likely other regulatory regions or an imprinting 
effect that is influencing PEAR1 expression in an allele specific manor independent of 
any potential enhancer effects identified by deletion of rs12041331. When cisPEAR1 KO 
was compared to BC1 iPSCs there was a reduction in expression found on the same allele 
as the deletion of rs12041331 bring relative expression down to ~30% for allele 2 when 
compared to ~75% for BC1. The reduction in total mRNA levels along with a change in 
the ratio of PEAR1 allelic expression is supportive of a cis-acting enhancer that acts in 
hematopoietic derived cells including megakaryocytes.  
The regulation of hematopoiesis and proper production of a full complement of 
blood derived cell lineages is a critical component of hemostasis, and general well being. 
Overproduction or lack of certain blood lineages has been reported in both Mendelian  
75 
disease as well as in cancer and through the study of rare forms of hematologic disease 
many key genes such as RUNX1, GATA1 or DBA in which mutations have been 
reported to cause highly penetrant forms of disease but variants of smaller impact have 
been difficult to identify and study. While initially PEAR1 was reported in the molecular 
mechanism of platelet aggregation; its more recent implication in regulating 
hematopoiesis and megakaryopoiesis made it an attractive target for an iPSC based 
genome editing protocol to further interrogate its function confirming its previously 
reported role in regulating growth and lineage commitment during megakaryopoiesis 
while also revealing an allele specific mechanism of gene regulation for an enhancer 
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